Showing 6271-6280 of 7527 results for "".
- Burt's Bees Data at WCD Highlights Power of Naturalshttps://practicaldermatology.com/news/burts-bees-data-at-wcd-highlights-power-of-naturals/2460062/New research from Burt's Bees supports findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan
- Study: Indoor Tanning Addiction May Be Abetted by Genetic and Psychiatric Factorshttps://practicaldermatology.com/news/study-indoor-tanning-addiction-may-be-abetted-by-genetic-and-psychiatric-factors/2460059/A combination of elevated symptoms of depression along with modifications in a gene responsible for dopamine activity appear to influence an addiction to indoor tanning in young, white non-Hispanic women, a new study suggests. The findings appear in the Annals of Behaviora
- Derm Residents Optimize Total Skin Exams Using Bioengineering Principleshttps://practicaldermatology.com/news/derm-residents-optimize-total-skin-exams-using-bioengineering-principles/2460058/Researchers at the Penn State Health Milton S. Hershey Medical Center are using engineering principles to improve the accuracy and efficiency of total body skin exams. There is no standardized method for performing a total body skin exam. D
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoi
- Revance Therapeutics Welcomes Jill Beraud to Board of Directorshttps://practicaldermatology.com/news/revance-therapeutics-welcomes-jill-beraud-to-board-of-directors/2460053/Jill Beraud is now a member of Revance Therapeutics, Inc.'s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand
- Study:Colorescience’s EnviroScreen Technology Fights Sun Damage, Environmental Factorshttps://practicaldermatology.com/news/studycoloresciences-enviroscreen-technology-fights-sun-damage-environmental-factors/2460051/Colorescience’s Patented EnviroScreen Technology suppresses free radical formation and demonstrates superior performance when tested against comparable products, according to a study in The Journal of Co
- Kylie Jenner Introduces Kylie Skinhttps://practicaldermatology.com/news/kylie-jenner-introduces-kylie-skin/2460046/Kylie Jenner’s new skincare lime, Kylie Skin, came out in true Kardashian-Jenner style with an all-pink party that included a roller skating rink, her famous family plus other A-listers. And the new line – which launched with six products
- Aestheia Imaging Launches Hologram-based Before and After Marketing Toolhttps://practicaldermatology.com/news/aestheia-imaging-launches-hologram-based-before-and-after-marketing-tool/2460044/Aestheia Imaging is rolling out XTHEIA, an interactive hologram display with a virtual consult assistant for medical office waiting rooms. The Dallas-based hologram content management and advertising subscription company will offe
- Report: Dermavant Files for $100M IPOhttps://practicaldermatology.com/news/report-dermavant-files-for-100m-ipo/2460043/Dermavant Sciences last week filed with the SEC to raise up to $100 million in an initial public offering, Renaissance Capital reports.
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t